» Articles » PMID: 37108136

Dual Blockade of TGF-β Receptor and Endothelin Receptor Synergistically Inhibits Angiotensin II-Induced Myofibroblast Differentiation: Role of ATR/G-Mediated TGF-β1 and ET-1 Signaling

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2023 Apr 28
PMID 37108136
Authors
Affiliations
Soon will be listed here.
Abstract

Angiotensin II (Ang II) upregulates transforming growth factor-beta1 (TGF-β1) and endothelin-1 (ET-1) in various types of cells, and all of them act as profibrotic mediators. However, the signal transduction of angiotensin II receptor (ATR) for upregulation of TGF-β1 and ET-1, and their effectors that play an essential role in myofibroblast differentiation, are not fully understood. Therefore, we investigated the ATR networking with TGF-β1 and ET-1 and identified the signal transduction of these mediators by measuring the mRNA expression of alpha-smooth muscle actin (α-SMA) and collagen I using qRT-PCR. Myofibroblast phenotypes were monitored by α-SMA and stress fiber formation with fluorescence microscopy. Our findings suggested that Ang II induced collagen I and α-SMA synthesis and stress fiber formation through the ATR/G axis in adult human cardiac fibroblasts (HCFs). Following ATR stimulation, G protein, not G subunit, was required for upregulation of TGF-β1 and ET-1. Moreover, dual inhibition of TGF-β and ET-1 signaling completely inhibited Ang II-induced myofibroblast differentiation. The ATR/G cascade transduced signals to TGF-β1, which in turn upregulated ET-1 via the Smad- and ERK1/2-dependent pathways. ET-1 consecutively bound to and activated endothelin receptor type A (ETR), leading to increases in collagen I and α-SMA synthesis and stress fiber formation. Remarkably, dual blockade of TGF-β receptor and ETR exhibited the restorative effects to reverse the myofibroblast phenotype induced by Ang II. Collectively, TGF-β1 and ET-1 are major effectors of ATR/G cascade, and therefore, negative regulation of TGF-β and ET-1 signaling represents a targeted therapeutic strategy for the prevention and restoration of cardiac fibrosis.

Citing Articles

Pathophysiology, molecular mechanisms, and genetics of atrial fibrillation.

Han P, Zhao X, Li X, Geng J, Ni S, Li Q Hum Cell. 2024; 38(1):14.

PMID: 39505800 DOI: 10.1007/s13577-024-01145-z.


Expression in Synovial Myofibroblasts: Implications for Female Osteoarthritis Pain through Propensity Score Matching Analysis.

Shibata N, Ohashi Y, Tsukada A, Iwase D, Aikawa J, Mukai M Medicina (Kaunas). 2024; 60(5).

PMID: 38792924 PMC: 11122993. DOI: 10.3390/medicina60050741.


New Therapeutics for Heart Failure: Focusing on cGMP Signaling.

Mangmool S, Duangrat R, Parichatikanond W, Kurose H Int J Mol Sci. 2023; 24(16).

PMID: 37629047 PMC: 10454066. DOI: 10.3390/ijms241612866.

References
1.
Shi-Wen X, Chen Y, Denton C, Eastwood M, Renzoni E, Bou-Gharios G . Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell. 2004; 15(6):2707-19. PMC: 420095. DOI: 10.1091/mbc.e03-12-0902. View

2.
Akhurst R, Padgett R . Matters of context guide future research in TGFβ superfamily signaling. Sci Signal. 2015; 8(399):re10. DOI: 10.1126/scisignal.aad0416. View

3.
Meng X, Nikolic-Paterson D, Lan H . TGF-β: the master regulator of fibrosis. Nat Rev Nephrol. 2016; 12(6):325-38. DOI: 10.1038/nrneph.2016.48. View

4.
Engebretsen K, Skardal K, Bjornstad S, Marstein H, Skrbic B, Sjaastad I . Attenuated development of cardiac fibrosis in left ventricular pressure overload by SM16, an orally active inhibitor of ALK5. J Mol Cell Cardiol. 2014; 76:148-57. DOI: 10.1016/j.yjmcc.2014.08.008. View

5.
Parichatikanond W, Luangmonkong T, Mangmool S, Kurose H . Therapeutic Targets for the Treatment of Cardiac Fibrosis and Cancer: Focusing on TGF-β Signaling. Front Cardiovasc Med. 2020; 7:34. PMC: 7075814. DOI: 10.3389/fcvm.2020.00034. View